ArticleBMJ open ophthalmology2025
Mitigating the risks: addressing smoking cessation in thyroid eye disease.
Article in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the effectiveness of verbal counselling and varenicline in achieving smoking cessation among patients with thyroid eye disease (TED) and to identify predictive factors associated with successful smoking cessation. METHODS AND ANALYSIS: A cross-sectional analysis of data from the Iran TED (IrTED) Registry was conducted. Patients' demographics and TED severity/activity were recorded. As a routine at the TED clinic in Rassoul Akram Hospital, since 2020, all smoking patients have undergone smoking cessation verbal counselling in the first and almost every subsequent visit session. The effectiveness of verbal counselling was assessed through a telephone survey. Retrospectively, the association between successful smoking cessation and disease severity/activity was evaluated. Prospectively, patients who failed or refused to quit smoking after counselling were offered varenicline. Acceptance, compliance and adherence rates were determined.
resultsWhile 379/685 patients of the IrTED 2013-2023 database (55.32%) reported no tobacco exposure, the remaining were active (n=117, 17.08%), passive (n=134, 19.56%) and former smokers (n=55, 8.02%). In 2020-2023, 73 active tobacco-smoking patients with TED were enrolled, all of whom received verbal cessation counselling at their first and subsequent visits. On the follow-up phone call, 51/73 were contacted, and 25/51 (49.01%) reported successful smoking cessation after verbal counselling. The remaining 26/51 smokers were offered varenicline (on the phone call); however, only 7/26 (26.92%) attended the prescription session. Of these patients, 3/7 (42.85%) completed the first month of treatment, and just 1/3 (33.33%) finished the 3-month course, successfully quitting smoking until the final follow-up (18 months). One patient (14.28%) reported constipation, and another one reported sleep paralysis (14.28%) as an adverse event.
conclusionVerbal counselling demonstrates effectiveness in smoking cessation for patients with TED, with nearly half of smokers successfully quitting the habit. Among those who failed to quit after verbal counselling, varenicline showed limited effectiveness, indicating poor compliance and motivation deficit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.